Elan begins 2009 with revenue jump
This article was originally published in Scrip
Executive Summary
Elan's first-quarter revenue increased by 14% to $245.1 million compared with the same period last year due to another strong performance from its multiple sclerosis treatment Tysabri (natalizumab).